Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) EBIT Margin: 2011-2025

Historic EBIT Margin for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -3,115.18%.

  • Abeona Therapeutics' EBIT Margin rose 1452276.00% to -3,115.18% in Q3 2025 from the same period last year, while for Sep 2025 it was -5,843.33%, marking a year-over-year increase of 246693.00%. This contributed to the annual value of -168,976.32% for FY2024, which is 16762960.00% down from last year.
  • As of Q3 2025, Abeona Therapeutics' EBIT Margin stood at -3,115.18%, which was up 45.33% from -5,698.00% recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' EBIT Margin ranged from a high of 97,191.67% in Q4 2021 and a low of -19,023.53% during Q4 2022.
  • Over the past 3 years, Abeona Therapeutics' median EBIT Margin value was -3,115.18% (recorded in 2025), while the average stood at -1,424.17%.
  • As far as peak fluctuations go, Abeona Therapeutics' EBIT Margin spiked by 9,767,433bps in 2021, and later plummeted by 11,621,520bps in 2022.
  • Over the past 5 years, Abeona Therapeutics' EBIT Margin (Quarterly) stood at 97,191.67% in 2021, then crashed by 11,621,520bps to -19,023.53% in 2022, then soared by 1,694,009bps to -2,083.44% in 2023, then soared by 3,034,107bps to 28,257.63% in 2024, then soared by 1,452,276bps to -3,115.18% in 2025.
  • Its EBIT Margin stands at -3,115.18% for Q3 2025, versus -5,698.00% for Q2 2025 and -6,322.76% for Q1 2025.